-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RZDuAQGiJc5fp5h2ZYJ0Ao8Fu/qAXa2ZGGIvQM/6PMvT4ZPcidPQqLBjKL13wtLF
 UBZhyQ3iDS0L2PASNh5iXw==

<SEC-DOCUMENT>0000842023-10-000013.txt : 20100504
<SEC-HEADER>0000842023-10-000013.hdr.sgml : 20100504
<ACCEPTANCE-DATETIME>20100504091616
ACCESSION NUMBER:		0000842023-10-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100504
DATE AS OF CHANGE:		20100504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		10795156

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): May 4, 2010

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on May 4,
2010, describing the results of operations for the quarter and nine months
ended March 31, 2010 and its financial condition as of March 31,
2010, is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and nine months
ended March 31, 2010 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated May 4, 2010.

         99.2 Segment information for the quarter and nine months
              ended March 31, 2010.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: May 4, 2010                    TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated May 4, 2010.

       99.2     Segment information for Techne Corporation for the quarter
                and nine months ended March 31, 2010.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>release310.txt
<DESCRIPTION>EARNINGS RELEASE DATED MAY 4, 2010
<TEXT>

           TECHNE CORPORATION RELEASES UNAUDITED THIRD QUARTER
                     RESULTS FOR FISCAL YEAR 2010

Minneapolis/May 4, 2010/-- Techne Corporation's (NASDAQ: TECH) consolidated
net earnings for the quarter ended March 31, 2010 increased 17.2% to $32.4
million or $.87 per diluted share compared with $27.6 million or $.74 per
diluted share for the quarter ended March 31, 2009.  The increase in net
earnings for the quarter was primarily due to a $4.7 million tax benefit,
equating to $.12 per share, resulting from a foreign exchange tax loss on
Techne's repatriation of 50 million pound sterling from R&D Systems Europe to
its U.S. based parent.  Techne had previously paid U.S. income taxes on the
foreign earnings that were included in the repatriated funds.

For the nine months ended March 31, 2010, Techne's consolidated net earnings
increased 5.0% to $83.9 million or $2.25 per diluted share compared with
$79.9 million or $2.10 per diluted share for the nine months ended March 31,
2009.  Net earnings for the nine month period would have decreased by
$636,000 (0.8%) without the tax benefit that resulted from the foreign
exchange tax loss from the repatriation of funds during the quarter ended
March 31, 2010.  This decrease in consolidated net earnings for the nine
months was the result of lower interest income offset by increased sales and
slightly improved gross margins.

Consolidated net sales for the quarter and nine months ended March 31, 2010
were $70.3 million and $202.3 million, respectively. This was a 3.6% and 1.6%
increase from the quarter and nine months ended March 31, 2009, respectively.
Consolidated net sales were positively affected by the strength of the U.S.
dollar as compared to foreign currencies, primarily the euro and the British
pound sterling. Excluding the effect of changes in foreign currency exchange
rates, consolidated net sales increased 1.8% and 0.3% for the quarter and
nine months ended March 31, 2010, respectively, from the comparable prior
year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $46.2 million for the
quarter ended March 31, 2010, an increase of 2.3% from $45.1 million in the
quarter ended March 31, 2009.  North American biotechnology sales to
industrial pharmaceutical and biotechnology customers increased 2.0% during
the third quarter of fiscal 2010 as compared to the third quarter of fiscal
2009.  Biotechnology sales to its academic customers and Pacific Rim
distributors and sales in China grew 3.5%, 12.6% and 10.3%, respectively, in
the third quarter of fiscal 2010.

Biotechnology sales were $132.6 million for the nine months ended March 31,
2010, an increase of 0.8% over the same period last year. North American
biotechnology sales to industrial pharmaceutical and biotechnology customers
decreased 2.5% during the nine months ended March 31, 2010 as compared to the
first nine months of fiscal 2009.  Biotechnology sales to its academic
customers and Pacific Rim distributors and sales in China grew 4.0%, 10.6%
and 20.7%, respectively, in the first nine months of fiscal 2010.

R&D Europe's net sales for the quarter and nine months ended March 31, 2010
were $19.2 million and $55.8 million, increases of 4.7% and 2.3%,
respectively, from the same prior-year periods.  R&D Europe's net sales
decreased 1.9% and 2.5% for the quarter and nine months ended March 31, 2010
when measured at currency rates in effect in the comparable prior periods.
The decreased net sales for the periods were mainly the result of lower sales
to pharmaceutical customers.

Hematology net sales for the quarter and nine months ended March 31, 2010
were $4.9 million and $13.9 million, increases of 11.4% and 7.7%,
respectively, compared to the quarter and nine months ended March 31, 2009.

Consolidated gross margins were 79.5% and 79.9% for the quarter and nine
months ended March 31, 2010, respectively, compared to 78.9% and 79.5% for
the quarter and nine months ended March 31, 2009, respectively. The increased
gross margins in fiscal 2010 are mainly the result of improved margins in the
biotechnology and hematology segments due to incremental profit on increased
sales volumes.

Selling, general and administrative expenses for the quarter and nine months
ended March 31, 2010 increased $605,000 (8.6%) and decreased $893,000 (3.5%),
respectively from the quarter and nine months ended March 31, 2009. The
increase in selling, general and administrative expense for the quarter ended
March 31, 2010 from the comparable prior-year period resulted from higher
profit sharing expense of $290,000 and annual wage, salary and benefit
increases.  The decrease in selling, general and administrative expenses for
the nine months ended March 31, 2010 from the comparable prior-year period
was due to lower stock compensation expense of $343,000 and lower profit
sharing expense of $435,000.

Research and development expenses for the quarter and nine months ended March
31, 2010 increased $516,000 (8.9%) and $1.3 million (7.4%), respectively,
from the quarter and nine months ended March 31, 2009.  The increase in
research and development expenses is the result of continuous development and
release of new high-quality biotechnology products upon which the Company's
future sales revenue growth is dependent.

Interest income decreased $464,000 and $3.2 million for the quarter and nine
months ended March 31, 2010, respectively, from the comparable prior-year
periods, primarily as a result of lower rates of return on cash and
available-for-sale investments, offset in part by higher cash and available-
for-sale investment balances.

The effective tax rates for the quarter and nine months ended March 31, 2010
were 21.8% and 28.8%, respectively. These effective rates were abnormally low
due to the tax benefit received following repatriation of funds from the U.K.
to the U.S.  Excluding this benefit, the effective tax rates for the quarter
and nine months ended March 31, 2010 would have been 33.1% and 32.8% for the
quarter and nine months ended March 31, 2010, respectively, as compared to
effective tax rates of 32.3% in both of the same prior-year periods. The
Company expects its fiscal 2010 effective income tax rate to range from
approximately 32.0% to 33.0%.

The Company repurchased 22,862 shares of its common stock during the third
quarter of fiscal 2010 for approximately $1.4 million. Approximately $66.1
million remains available for the repurchase of shares under currently open
authorizations.


Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning
of the Private Litigation Reform Act. Such statements involve risks and
uncertainties that may affect the actual results of operations. The following
important factors, among others, have affected and, in the future, could
affect the Company's actual results: the introduction and acceptance of new
biotechnology and hematology products, the levels and particular directions
of research by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price competition,
general economic conditions, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in our press releases due to
new information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                   *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.


Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854


                             TECHNE CORPORATION
                    CONSOLIDATED STATEMENTS OF EARNINGS
                   (In thousands, except per share data)
                                  (Unaudited)

                                        QUARTER ENDED    NINE MONTHS ENDED
                                      ----------------  ------------------
                                      3/31/10  3/31/09   3/31/10   3/31/09
                                      -------  -------  --------  --------
Net sales                             $70,278  $67,866  $202,333  $199,066
Cost of sales                          14,399   14,316    40,629    40,832
                                      -------  -------  --------  --------
Gross margin                           55,879   53,550   161,704   158,234
                                      -------  -------  --------  --------
Operating expenses:
  Selling, general and administrative   7,666    7,061    24,711    25,604
  Research and development              6,325    5,809    18,870    17,565
  Amortization of intangible assets       240      240       720       720
                                      -------  -------  --------  --------
    Total operating expenses           14,231   13,110    44,301    43,889
                                      -------  -------  --------  --------
Operating income                       41,648   40,440   117,403   114,345
Other income (expense):
  Interest income                       1,040    1,504     3,364     6,596
  Other non-operating expense, net     (1,249)  (1,103)   (2,922)   (3,002)
                                      -------  -------  --------  --------
    Total other (expense) income         (209)     401       442     3,594
                                      -------  -------  --------  --------
Earnings before income taxes           41,439   40,841   117,845   117,939
Income taxes                            9,051   13,200    33,964    38,083
                                      -------  -------  --------  --------
Net earnings                          $32,388  $27,641  $ 83,881  $ 79,856
                                      =======  =======  ========  ========
Earnings per share:
 Basic                                $  0.87  $  0.74  $   2.25  $   2.10
 Diluted                              $  0.87  $  0.74  $   2.25  $   2.10
Weighted average common
 shares outstanding:
  Basic                                37,292   37,427    37,263    37,986
  Diluted                              37,380   37,499    37,357    38,085




                              TECHNE CORPORATION
                          CONSOLIDATED BALANCE SHEETS
                                (In thousands)
                                  (Unaudited)
                                                       3/31/10    6/30/09
                                                      --------   --------
ASSETS
Cash and equivalents                                  $108,236   $160,940
Short-term available-for-sale investments               44,922     41,947
Trade accounts receivable                               34,527     29,516
Other receivables                                        1,395      1,637
Inventory                                               13,451     11,269
Other current assets                                    16,791     10,158
                                                      --------   --------
  Current assets                                       219,322    255,467
Available-for-sale investments                         154,360     61,863
Property and equipment, net                             97,745    100,133
Goodwill and intangible assets, net                     27,352     28,072
Other non-current assets                                23,113     26,470
                                                      --------   --------
  Total assets                                        $521,892   $472,005
                                                      ========   ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities                                   $ 19,748   $ 15,523
Stockholders' equity                                   502,144    456,482
                                                      --------   --------
  Total liabilities and stockholders' equity          $521,892   $472,005
                                                      ========   ========

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>seg310.txt
<DESCRIPTION>SEGMENT RESULTS FOR MARCH 2010
<TEXT>
                          SEGMENT INFORMATION
                TECHNE CORPORATION AND SUBISIDARIES
            (in thousands of $'s, except per share data)

                                                       Increase (Decrease)
                             Fiscal 2010               From Fiscal 2009
              ----------------------------------  ------------------------
               First Second  Third         % of   First Second  Third
                Qtr   Qtr     Qtr    YTD   Sales   Qtr    Qtr    Qtr    YTD
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Sales         66,534 65,521 70,278 202,333  100% (2,790) 3,645  2,412  3,267
Cost of sales 12,901 13,329 14,399  40,629   20%   (185)  (101)    83   (203)
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Gross margin  53,633 52,192 55,879 161,704   80% (2,605) 3,746  2,329  3,470

Gross margin
 percentage    80.6%  79.7%  79.5%   79.9%

SG&A expense   8,038  9,007  7,666  24,711   12%   (802)  (696)   605   (893)
R&D expense    6,154  6,391  6,325  18,870   10%    244    545    516  1,305
Amortization
 expense         240    240    240     720    --     --     --     --     --
Interest
 income       (1,168)(1,156)(1,040) (3,364)  (1%) 1,719  1,049    464  3,232
Other non-
 operating
 ex., net        662  1,011  1,249   2,922    1%   (525)   299    146    (80)
              ------ ------ ------ ------- -----  ----- ------  -----  -----
              13,926 15,493 14,440  43,859   22%    636  1,197  1,731  3,564
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Earnings
 before
 income taxes 39,707 36,699 41,439 117,845   58% (3,241) 2,549    598    (94)
Income taxes  12,935 11,978  9,051  33,964   17% (1,420) 1,450 (4,149)(4,119)
              ------ ------ ------ ------- -----  ----- ------  -----  -----
              26,772 24,721 32,388  83,881   41% (1,821) 1,099  4,747  4,025
              ====== ====== ====== ======= =====  ===== ======  =====  =====
Diluted
 earnings
 per share       .72    .66    .87    2.25
Weighted avg.
 diluted shares
 outstanding  37,339 37,353 37,380  37,357




                                  BIOTECHNOLOGY  (1)
                                (in thousands of $'s)

                                                       Increase (Decrease)
                             Fiscal 2010               From Fiscal 2009
              ----------------------------------  ------------------------
               First Second  Third         % of   First Second  Third
                Qtr   Qtr     Qtr    YTD   Sales   Qtr    Qtr    Qtr    YTD
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Sales         51,696 50,703 54,236 156,635  100% (2,203) 2,060    518    375
Intersegment
 sales        (7,668)(8,282)(8,057)(24,007)          94     29    522    645
              ------ ------ ------ -------        ----- ------  -----  -----
              44,028 42,421 46,179 132,628       (2,109) 2,089  1,040  1,020

Cost of sales  9,885 10,126 11,159  31,170   20%   (362)  (964)    79 (1,247)
Intersegment
 sales        (7,598)(7,753)(8,336)(23,687)        (137)   586    158    607
              ------ ------ ------ -------  ----- ----- ------  -----  -----
               2,287  2,373  2,823   7,483         (499)  (378)   237   (640)

Gross margin  41,741 40,048 43,356 125,145   80% (1,610) 2,467    803  1,660

Gross margin
 percentage    80.9%  80.0%  79.4%   80.1%

SG&A expense   4,734  5,056  4,625  14,415    9%   (407)  (362)   363   (406)
R&D expense    5,956  6,190  6,127  18,273   12%    239    547    505  1,291
Amortization
 expense         240    240    240     720    --     --     --     --     --
Interest, net   (771)  (772)  (706) (2,249)  (1%)   313    198    147    658
Other expense      2      1     --       3    --      4     --     (1)     3
              ------ ------ ------ ------- -----  ----- ------  -----  -----
              10,161 10,715 10,286  31,162   20%    149    383  1,014  1,546
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Pretax result 31,580 29,333 33,070  93,983   60% (1,759) 2,084   (211)   114
              ====== ====== ====== ======= =====  ===== ======  =====  =====

(1)  Includes R&D Systems' Biotechnology Division, BiosPacific, Inc.
and R&D China


                            R&D SYSTEMS EUROPE
                      (in thousands of Br. pounds)

                                                       Increase (Decrease)
                             Fiscal 2010               From Fiscal 2009
              ----------------------------------  ------------------------
               First Second  Third         % of   First Second  Third
                Qtr   Qtr     Qtr    YTD   Sales   Qtr    Qtr    Qtr    YTD
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Sales         10,881 11,462 12,296  34,639  100%    706    265   (420)   551
Cost of sales  5,061  5,288  5,824  16,173   47%    801    (73)  (716)    12
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Gross margin   5,820  6,174  6,472  18,466   53%    (95)   338    296    539

Gross margin
 percentage    53.5%  53.9%  52.6%   53.3%

SG&A expense   1,191  1,318  1,260   3,769   11%    (33)   (46)    69    (10)
Interest         (87)   (79)   (68)   (234)  (1%)   703    504    167  1,374
Exchange loss/
 (gain)          (89)    61    237     209    --   (349)    96     74   (179)
              ------ ------ ------ ------- -----  ----- ------  -----  -----
               1,015  1,300  1,429   3,744   10%    321    554    310  1,185
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Pretax result  4,805  4,874  5,043  14,722   43%   (416)  (216)   (14)  (646)
              ====== ====== ====== ======= =====  ===== ======  =====  =====



                              R&D SYSTEMS EUROPE
                           (in thousands of $'s)

                                                       Increase (Decrease)
                             Fiscal 2010               From Fiscal 2009
              ----------------------------------  ------------------------
               First Second  Third         % of   First Second  Third
                Qtr   Qtr     Qtr    YTD   Sales   Qtr    Qtr    Qtr    YTD
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Sales         17,838 18,775 19,161  55,774  100% (1,103) 1,491    868  1,256
Cost of sales  8,295  8,664  9,071  26,030   47%    364    390   (334)   420
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Gross margin   9,543 10,111 10,090  29,744   53% (1,467) 1,101  1,202    836

Gross margin
 percentage    53.5%  53.9%  52.7%   53.3%

SG&A expense   1,952  2,159  1,967   6,078   11%   (331)    65    253    (13)
Interest        (143)  (128)  (108)   (379)  (1%) 1,328    778    230  2,336
Exchange loss/
 (gain)         (145)    99    372     326    --   (621)    94    134   (393)
              ------ ------ ------ ------- -----  ----- ------  -----  -----
               1,664  2,130  2,231   6,025   10%    376    937    617  1,930
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Pretax result  7,879  7,981  7,859  23,719   43% (1,843)   164    585 (1,094)
              ====== ====== ====== ======= =====  ===== ======  =====  =====




                                      HEMATOLOGY
                                (in thousands of $'s)

                                                       Increase (Decrease)
                             Fiscal 2010               From Fiscal 2009
              ----------------------------------  ------------------------
               First Second  Third         % of   First Second  Third
                Qtr   Qtr     Qtr    YTD   Sales   Qtr    Qtr    Qtr    YTD
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Sales          4,668  4,325  4,938  13,931  100%    422     65    504    991
Cost of sales  2,319  2,292  2,505   7,116   51%    (50)  (113)   180     17
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Gross margin   2,349  2,033  2,433   6,815   49%    472    178    324    974

Gross margin
 percentage    50.3%  47.0%  49.3%   48.9%

SG&A expense     370    366    346   1,082    8%    (66)   (32)    36    (62)
R&D expense      198    201    198     597    4%      5     (2)    11     14
Interest, net    (72)   (72)   (65)   (209)  (1%)    30     19     15     64
              ------ ------ ------ ------- -----  ----- ------  -----  -----
                 496    495    479   1,470   11%    (31)   (15)    62     16
              ------ ------ ------ ------- -----  ----- ------  -----  -----
Pretax result  1,853  1,538  1,954   5,345   38%    503    193    262    958
              ====== ====== ====== ======= =====  ===== ======  =====  =====




                              CORPORATE AND OTHER (2)
                                (in thousands of $'s)

                                                   Increase (Decrease)
                               Fiscal 2010         From Fiscal 2009
                ----------------------------  ------------------------
                 First Second  Third          First Second  Third
                  Qtr   Qtr     Qtr    YTD     Qtr    Qtr    Qtr    YTD
                ------ ------ ------ -------  ----- ------  -----  -----
Interest income    182    184    161     527    (48)   (54)   (72)  (174)
Rental income       81    115     83     279    (18)   (16)   (32)   (66)
                ------ ------ ------ -------  ----- ------  -----  -----
                   263    299    244     806    (66)   (70)  (104)  (240)

SG&A expense       982  1,426    728   3,136      2   (367)   (47)  (412)
Other-Building
 expenses          548    530    593   1,671     (5)   (21)    20     (6)
Other-Equity
 Investment
 losses            338    496    367   1,201     79    210    (39)   250
                ------ ------ ------ -------  ----- ------  -----  -----
                 1,868  2,452  1,688   6,008     76   (178)   (66)  (168)
                ------ ------ ------ -------  ----- ------  -----  -----
Pretax result   (1,605)(2,153)(1,444) (5,202)  (142)   108    (38)   (72)
                ====== ====== ====== =======  ===== ======  =====  =====


(2) Unallocated corporate expenses and Techne's share of losses
 by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
